Jump to content

Xolair (Omalizumab)


rss

Recommended Posts

XOLAIR_75mg_150mg_Logo_4C.png

Xolair (Omalizumab), a brand name medication originally designed to reduce sensitivity to allergens, has been used to treat a variant of rosacea, Rosacea Lymphedema (Morbihan Disease)

"Omalizumab is used to treat people with severe, persistent allergic asthma, uncontrollable with oral or injectable corticosteroids." [1]

One paper concludes, "The abundance of mast cells, producing vasoactive substances, proteases and cathelicidins, such as Cath-37, may be important in the pathogenesis of rosacea as well as of MS, and studies indicate that the antihistamine ketotifen shows beneficial outcome in the treatment of rosacea. Omalizumab is a humanised monoclonal antibody that binds the circulating IgE antibodies and may stabilise mast cells in the treatment of chronic urti- caria. Typical flushes in MS and rosacea are similar to the temporary erythematous swellings observed in urticaria and angioedema. Accordingly, we hypothesize that omalizumab could stabilize mast cells in MS and reduce the temporary swelling." [2]

Reply to this Topic

There is a reply to this topic button somewhere on the device you are reading this post. If you never heard about this topic and you learned about it here first, wouldn't it be a gracious act on your part to show your appreciation for this topic by registering with just your email address and show your appreciation with a post?  And if registering is too much to ask, could you post your appreciation for this topic by finding the START NEW TOPIC button in our guest forum where you don't have to register?  We know how many have viewed this topic because our forum software shows the number of views. However, most rosaceans don't engage or show their appreciation for our website and the RRDi would simply ask that you show your appreciation, please, simply by a post.  

End Notes 

[1] Omalizumab, Wikipedia

[2] Acta Derm Venereol. 2019 Jun 01;99(7):677-678
Morbihan Syndrome Successfully Treated with Omalizumab.
Kafi P, Edén I, Swartling C

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...

Important Information

Terms of Use